Review

Continence and complications rates after male slings as primary surgery for post-prostatectomy incontinence: A systematic review

Maria Angela Cerruto, Carolina D’Elia, Walter Artibani

Department of Surgery Urology Clinic, University of Verona, Italy.

Summary

Objectives: to analyze continence and complications rates after male slings as first line surgical treatment, in order to improve patient counseling for the management of SUI postprostatectomy.

Method: A MedLine search using specified search terms was done on January 23, 2012. This research rendered 160 records.

Results: No controlled trial was available for analysis. The majority of papers dealing with outcome and complications came from a few centres. At a median follow-up of 15 months the pooled cure rates for all kinds of slings was 77.4%; in the Advance group the pooled cure rates was 72.5%; in the InVance group it was 74.2% while in the Remex group it was 84.3%.

Conclusions: Only a few number observational studies addressed review selection criteria. The pooled overall cure rates is high but there are no data concerning reliable pre- and postoperative prognostic factors affecting treatment failure and complications rates, thus it is not possible to have suitable criteria for a better patient selection. The statistically pooled results obtained should be interpreted with caution because of several limitations due to several study selection limitations: observational study design, few number of analysed studies, heterogeneity, lack of outcome definition and standardisation, between-study variability, high risk of bias.

Key words: Sling; Male incontinence; Radical prostatectomy; Continence; Complications.

Submitted 17 July 2012, Accepted 31 December 2012

No conflict of interest declared

Introduction

Radical prostatectomy (RP) is the most common treatment option for prostate cancer, with more than 80 000 RPs annually in the USA (1). Urinary incontinence (UI) is a common and costly complication in men after RP, often adversely affecting their quality of life (QoL) (2). Despite improvements in surgical techniques and a better understanding of pelvic anatomy, the reported stress urinary incontinence (SUI) rates are between 5% and 48% (3). Conservative treatment of the urinary leakage represents the first line management of UI after RP, but the value of the various conservative approaches to treat postprostatectomy UI after RP remains uncertain (4). The last Cochrane systematic review on this topic found that there was conflicting information about the benefit of pelvic floor muscle training for either prevention or treatment of urine leakage after prostate surgery. More research of better quality is needed to assess conservative management (4). When conservative treatments are unsuccessful after a reasonable period of time (e.g. 8-12 weeks), invasive therapies should be considered (5). According to the last International Consultation on Incontinence Recommendations, for SUI due to sphincter incompetence the recommended option is the artificial urinary sphincter (AUS) (Grade B); other options, such as a male sling, may be considered (Grade C) (5). These low grades of recommendation can be explained by the fact that, although there are several options for surgical treatment of UI after prostatectomy, surprisingly only one randomised clinical trial was identified in the literature, comparing AUS implantation and injectable treat-
Continence and complications rates after male slings as primary surgery for post-prostatectomy incontinence: A systematic review

METHODS
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist was used to help guide this report (8). We conducted a PubMed database search through January 2012 for relevant prospective cohort studies and case series that met the following inclusion criteria: English language; adults with SUI postprostatectomy who underwent male slings as first surgical option for continence recovery; studies carried out on ≥ 20 patients with a mean follow-up of ≥ 1 year; because the majority of papers dealing with outcome and complications came from a few centres, only the most recent publication(s) from each centre were included to avoid the same patients being presented several times.

Multiple free-text searches were performed including the following terms: Suburethral Slings, Suburethral Sling, Transobturator Tape, Transobturator Tapes, Transobturator Suburethral Tape, Trans-Obslurator Tape, Male sling, Male slings, Argus sling, Advance sling, Invance sling, Remexx sling, Urinary Incontinence, Urinary Stress Incontinence, Post Prostatectomy, Post-prostatectomy, Prostatectomies, Suprapubic Prostatectomies, Suprapubic Prostatectomy, Retropubic Prostatectomies, Retropubic Prostatectomy. In addition, other significant studies cited in the reference lists of the selected papers were considered. Both authors independently reviewed all records by title and abstract followed by full-text articles for those meeting the screening criteria. Both authors independently abstracted data on study details (authors, year of publication, journal, location, study design), patient characteristics (age, length of follow-up, time period of surgery, type of prostatectomy), sling types, outcomes (overall cure rates, complications rates). A single reviewer (MAC) assessed risk of bias at the study level. The Downs-Black quality assessment tool (9) was used for nonrandomized studies; a score ≥ 17 of 31 was considered higher quality.

Few studies presented their original data in a format amenable to meta-analysis. Articles that presented data as a median and range were converted to means according to Hozo et al. (10). A single weight-adjusted mean or proportion for each variable or outcome was computed for each of the nonrandomized studies. To derive pooled estimates of proportions for the outcomes explored, random effects models were used. Pooling was conducted using Comprehensive Meta Analysis Version 2.2.046 (Englewood, NJ). Given that this review assessed measures of prevalence, publication bias was not evaluated.

RESULTS AND DISCUSSION
From screening 160 records, 49 full-text articles were retrieved with only 5 articles included in the systematic review (Figure 1). The 5 included articles involved 356 participants living in 8 countries with a median follow-up after sling implant of 15 months (interquartile range 12–21) and sling surgeries conducted between 2002 and 2009. Patients’ mean age at time of surgery was 68.06 (standard deviation, 1.37) years. Study characteristics and quality are summarized in Table 1 (11-15).

Table 1.
Characteristics of included observational studies.

<table>
<thead>
<tr>
<th>Source</th>
<th>Publication year</th>
<th>Journal</th>
<th>Nation</th>
<th>Patient number</th>
<th>Time period of surgery</th>
<th>RP rate (%)</th>
<th>Patient mean age</th>
<th>Sling type</th>
<th>Mean follow-up</th>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grise P, et al. (11)</td>
<td>2011</td>
<td>Urology</td>
<td>France</td>
<td>103</td>
<td>2007-2009</td>
<td>94.8</td>
<td>69.4</td>
<td>I-STOP TOMS</td>
<td>12</td>
<td>high</td>
</tr>
<tr>
<td>Delin EJ, et al. (13)</td>
<td>2010</td>
<td>J Urol</td>
<td>The Netherlands</td>
<td>35</td>
<td>2007-2008</td>
<td>80</td>
<td>68.5</td>
<td>Advance</td>
<td>12</td>
<td>high</td>
</tr>
<tr>
<td>Gallagher BL, et al. (14)</td>
<td>2007</td>
<td>Urology</td>
<td>USA</td>
<td>31</td>
<td>2002-2005</td>
<td>94</td>
<td>66</td>
<td>Invance</td>
<td>15</td>
<td>high</td>
</tr>
<tr>
<td>Sousa-Encarnação A, et al. (15)</td>
<td>2007</td>
<td>Eur Urol</td>
<td>Spain, Italy, Greece, Germany, Portugal</td>
<td>51</td>
<td>2002-2005</td>
<td>84.3</td>
<td>69</td>
<td>Remexx</td>
<td>32</td>
<td>high</td>
</tr>
</tbody>
</table>

Figure 1.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

160 records identified by Medline search

49 records for full text screen

5 records included in the analysis
The types of slings considered were: the 4-arm I-STOP TOMS transobturateur male sling (CL Medical) (11) (that is an adapted version of the 2-arm TOMS bulbar sling) (16); the AdVance sling (12, 13) (a retourethral transobturateur sling working by relocating the lax and descended supporting structures of the posterior urethra and sphincter region after prostate surgery into the former prostatetomy position) (17); the InVance sling (American Medical System) (14) (a nonadjustable sling system characterised by a silicon-coated polyester sling positioned under the bulbar urethra via a perineal incision to obtain a compression) (18); the Remeex system (15) (a readjustable sling positioned under the bulbar urethra) (19). Figure 2 pooled the continence rates achieved after the analysed sling procedures. At a median follow-up of 15 months the pooled cure rates for all kinds of slings was 77.4% (95% CI 66.0-85.8); in the AdVance group the pooled cure rates was 72.5 (95% CI 65.0-68.8); in the InVance group it was 74.2% (95% CI 56.3-86.5) while in the Remeex group it was 84.3% (95% CI 71.6-92). These statistically pooled results should be interpreted with caution because of several limitations due to several study selection limitations: study design, number of analysed studies, between-study variability, high risk of bias. Concerning overall complications rate it was impossible to obtain this information. Grise et al. did not report complications, such as bladder perforation, intraoperative bleeding (> 200 mL), or nerve, bowel, or vascular injury, occurred during the implant of the I-STOP TOMS male sling, except for wounding of the corpus cavernosum in 4% of patients (11). The authors reported a successful catheter removal 48 hours after surgery in 98.9% of patients. Moreover, 97.3%-100% were free of urinary tract infection at the different follow-up visits, and 96.5%-100% of the patients had not experienced urinary tract infection in the month before the visits. Immediately after the AdVance implant, Cornu et al. (12) reported only two cases of dysuria, one case of perineal haematoma and two cases of perineal paresthesia. During follow-up 10% of 10% of patients had perineal pain and 14% of patients had mild dysuria, but none require surgical management. In the other case series (13) complications developed in 2 patients, including slinging infection and postoperative urinary retention in 1 each. In the InVance group (14) 4 patients (13%) underwent sling removal; two removals were because of infection (both of these patients had undergone previous radiotherapy), one because of pain, and one because of the lack of improve-

**CONCLUSION**

The male slings approved for use currently include a variety of types: bone anchored slings, adjustable slings, and transoburator slings. This review tried to systematically assessed the outcomes of male slings used as the first line treatment, after conservative therapy failure, for the treatment of post-prostatectomy SUI. Only a few number of the observational studies published in the literature addressed review selection criteria. The pooled overall cure rates is high but there are no data concerning reliable pre- and postoperative prognostic factors affecting treatment failure and complications rates, thus it is not possible to have suitable criteria for a better patient selection.

The statistically pooled results obtained should be interpreted with caution because of several limitations due to several study selection limitations: observational study design, few number of analysed studies, heterogeneity, lack of outcome definition and standardisation, between-study variability, high risk of bias. In order to better select patients for male slings in the management of post-prostatectomy SUI as first line treatment, it is mandatory to carried out both well designed randomized clinical trials and longitudinal cohort studies, using standardised protocols and outcome measures.

**REFERENCES**


Correspondence
Maria Angela Cerruto, MD
martaangela.cerruto@univr.it
Carolina D’Elia, MD, FEBU (Corresponding Author)
karolina.delia@gmail.com
Walter Artibani, MD
walter.artibani@univr.it
Urology Clinic, Department of Surgery
University of Verona & AOUI, p le L Scuro 10 - 37134 Verona, Italy